Maury Raycroft
Stock Analyst at Jefferies
(1.40)
# 3,541
Out of 5,048 analysts
53
Total ratings
32.5%
Success rate
-7.47%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.40 | +14.29% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $434.07 | +26.48% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.13 | +14.19% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $18.56 | -19.18% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.31 | +51.52% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $12.30 | +330.89% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $3.74 | +113.90% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.58 | +418.76% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $1.86 | +276.34% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $2.38 | +152.10% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $8.01 | +137.20% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $4.56 | +228.95% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $34.03 | +14.60% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.72 | +736.24% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $2.42 | +850.41% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $10.02 | +1,846.11% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $6.86 | +60.35% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $25.94 | -76.87% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $39.61 | +89.35% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $9.10 | +20.88% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $15.43 | +74.98% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.07 | +141.55% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $75.19 | -36.16% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.03 | +298.79% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.20 | +1,919.23% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $61.97 | +177.55% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $3.95 | +1,089.87% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $13.07 | +221.35% | 3 | Nov 1, 2017 |
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.40
Upside: +14.29%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $434.07
Upside: +26.48%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.13
Upside: +14.19%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $18.56
Upside: -19.18%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.31
Upside: +51.52%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $12.30
Upside: +330.89%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.74
Upside: +113.90%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.58
Upside: +418.76%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $1.86
Upside: +276.34%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $8.01
Upside: +137.20%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $4.56
Upside: +228.95%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $34.03
Upside: +14.60%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.72
Upside: +736.24%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $2.42
Upside: +850.41%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $10.02
Upside: +1,846.11%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $6.86
Upside: +60.35%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $25.94
Upside: -76.87%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $39.61
Upside: +89.35%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $9.10
Upside: +20.88%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $15.43
Upside: +74.98%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.07
Upside: +141.55%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $75.19
Upside: -36.16%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $9.03
Upside: +298.79%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.20
Upside: +1,919.23%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $61.97
Upside: +177.55%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $3.95
Upside: +1,089.87%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $13.07
Upside: +221.35%